Electrocardiography and cardiac magnetic resonance imaging in the detection of left ventricular hypertrophy : the impact of indexing methods by Matusik, Paweł et al.
O R I G I N A L  A R T I C L E  ECG and CMR imaging in the detection of LVH 889
LVH reflects an increased probability of morbid­
ity and mortality.3,4 Therefore, the proper diag­
nosis of LVH is of value in the medical decision­
­making process.
Multiple electrocardiographic (ECG) criteria 
for the diagnosis of LVH (ECG ­LVH) have been 
proposed and some of them are widely used in 
IntroductIon Left ventricular hypertrophy 
(LVH) is associated with elevated left ventricu­
lar (LV) volumes, increased wall thickness, or 
may be a combination of these pathophysiolog­
ical changes.1 In patients with LVH, anatomical 
alterations are associated with changes in elec­


















Background Discrepancies between increased left ventricular mass (LVM) and electrocardiographic 
(ECG) criteria for the diagnosis of left ventricular hypertrophy (LVH) are described in the literature.
aims This study aimed to evaluate the usefulness of ECG criteria in the diagnosis of LVH, as determined 
by cardiac magnetic resonance (CMR) imaging, using various LVM indexing methods.
methods We included 53 patients who underwent CMR imaging and had electrocardiograms of 
appropriate quality available in their medical records. The majority of the study patients had cardiovascular 
diseases. We defined CMR ‑LVH as increased LVM, also assessed after LVM indexing to body surface area 
(LVM / BSA), height1.7, height2.7, or as the percentage of predicted LVM (%pLVM). To determine ECG ‑LVH, 
10 different ECG‑LVH criteria were used.
results The prevalence of CMR ‑LVH ranged from 11% (for %pLVM) to 72% (for LVM / BSA). At the same 
time, for a single criterion, the prevalence of ECG ‑LVH ranged between 1.9% (for R wave amplitude in 
lead V5 / V6 greater than 2.6 mV, Sokolow–Lyon product, and Gubner–Ungerleider criterion) and 45.3% 
(for Peguero–Lo Presti criterion), showing high sensitivity, from 55.3% (95% CI, 38.3–71.4) to 100% 
(95% CI, 54.1–100). The sensitivity of ECG ‑LVH criteria when all criteria were applied together ranged 
from 57.9% (95% CI, 40.8–73.7) to 100% (95% CI, 63.1–100). The best performance regarding the endpoint 
of CMR ‑LVH diagnosis after LVM indexing was achieved by the Peguero–Lo Presti and Cornell criteria 
(area under the curve, 0.621–0.876; P, 0.001–0.17).
conclusions The diagnosis of LVH strongly depends on ECG‑ and CMR ‑based definitions. The Peguero–Lo Presti 
criterion and the Cornell criteria, which are sex ‑specific, may provide the highest level of diagnostic accuracy 
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etiologies of myocardial disease, and improve­
ment of clinical decision making and risk strat­
ification.15,17-21 However, CMR imaging has abso­
lute and relative contraindications, which are 
similar to those of magnetic resonance imag­
ing, and requires sufficient expertise for appro­
priate study interpretation. Additionally, there 
are other concerns regarding the optimal assess­
ment of LVM. This is partially due to the fact 
that LVM depends on multiple factors, espe­
cially body size; thus, several methods to index 
LVM have been proposed.22-26
Our aim was to evaluate the usefulness of 
ECG ­LVH criteria in the diagnosis of LVH, as de­
termined by CMR imaging, using various LVM 
indexing (LVMi) methods.
Methods study population Our study in­
cluded real ­world patients, the majority of whom 
had cardiovascular diseases, underwent CMR 
imaging between 2011 and 2015 in the Depart­
ment of Diagnostic Imaging at the University 
Hospital in Kraków (Poland), and had an ECG 
of appropriate quality for analysis in the avail­
able medical records. Clinical data obtained 
from a structured medical record review includ­
ed baseline clinical and demographic character­
istics and medication history.19 Patients with 
right bundle branch block, left bundle branch 
block, left anterior fascicular block, or ventric­
ular preexcitation were excluded from the cur­
rent analysis. The study was approved by the lo­
cal ethics committee.
electrocardiographic analysis Standard 
12­lead ECGs were recorded at a 25 mm/s paper 
speed and calibration of 10 mm/mV. The ECGs 
were then interpreted by a reader who was ini­
tially blinded to the patient’s CMR imaging data. 
The duration of QRS complexes and the ampli­
tudes of R and S waves were measured. We evalu­
ated 10 different ECG ­LVH criteria, including all 
standard criteria recommended in the statement 
by the Working Group on Noninvasive Electro­
cardiology and Telemedicine of the Polish Cardi­
ac Society as well as the novel Peguero–Lo Presti 
criterion.4,6-8,14 A “cumulative criterion” was de­
fined as positive when at least 1 ECG ­LVH crite­
rion was fulfilled. The assessment of ECG ­LVH 
and analyzed criteria are described in detail in 
FIgURE 1 and in Supplementary material, Table S1.
cardiac magnetic resonance imaging Cardi­
ac magnetic resonance imaging was performed 
using a 1.5 Tesla GE Signa HDxt scanner (Gener­
al Electric, Milwaukee, Wisconsin, United States). 
The fast imaging employing steady ­state acqui­
sition cine technique was used to acquire imag­
es. Contrast ­enhanced scans performed after 
gadolinium injection, as described and reported 
elsewhere,19 were obtained in 48 study patients 
clinical practice.4-8 The statement by the Amer­
ican Heart Association / American College of 
Cardiology Foundation / Heart Rhythm Soci­
ety from 2009 included over 35 ECG ­LVH cri­
teria.5 A more recent statement by the Working 
Group on Noninvasive Electrocardiology and 
Telemedicine of the Polish Cardiac Society rec­
ommended 13 different ECG ­LVH criteria, de­
pending on the presence of ventricular conduc­
tion disorders.8 Voltage and non­voltage chang­
es in QRS complexes are used for LVH screen­
ing in most of these criteria.3 However, despite 
the clinical significance of ECG ­LVH criteria, 
they are generally characterized by low sensitiv­
ity; therefore, novel or modified ECG ­LVH cri­
teria have been proposed.6,9-12 The intra­ and in­
terobserver variability (according to the Shrout 
and Fleiss analysis with fixed effect) for select­
ed ECG ­LVH criteria was 0.94 and 0.8, respec­
tively.6 Discordance between increased LV mass 
(LVM) and ECG ­LVH criteria is a disadvantage 
of using ECG ­based criteria for LVH detection.3 
Using ECG ­based criteria, some patients with­
out LVH may be improperly diagnosed as hav­
ing LVH. On the other hand, some patients may 
not fulfil current ECG ­based definitions, despite 
the presence of LVH. This can be the case when 
using a single ECG­LVH criterion. Therefore, to 
increase accuracy of ECG ­LVH diagnosis, the use 
of multiple ECG ­LVH criteria is recommended.5,8
Currently, cardiac magnetic resonance (CMR) 
imaging is the gold standard in the diagnosis of 
LVH.13 When used for the assessment of LVM, it 
has higher reproducibility and precision com­
pared with echocardiography, as it provides good 
contrast at endocardial borders and there is no 
need for geometric assumptions.14,15 The repro­
ducibility of LVM measurement by CMR imag­
ing reflected by a mean weighted intraobserver 
variability is 4.8 g, whereas interobserver vari­
ability is 9 g.16 Furthermore, CMR imaging pro­
vides detailed images, which can reveal local 
wall thickening in specific LV segments.15 Pre­
vious studies have shown the value of CMR im­
aging in the diagnostic workup of LVH, differ­
entiation between ischemic and nonischemic 
whAt’s new?
The diagnosis of left ventricular hypertrophy (LVH) strongly depends on 
electrocardiographic and cardiac magnetic resonance imaging–based definitions. 
The incidence of LVH diagnosed with the use of cardiac magnetic resonance 
imaging–based criteria may range from 11% (for predicted left ventricular mass) 
to 72% (for left ventricular mass indexed to body surface area). Diagnosed using 
electrocardiographic criteria, the incidence of LVH may range from 1.9% (for R 
wave amplitude in lead V5 / V6 greater than 2.6 mV, Sokolow–Lyon product, and 
Gubner–Ungerleider criterion) to 45.3% (for Peguero–Lo Presti criterion). 
The novel Peguero–Lo Presti criterion and the Cornell criteria, which are sex‑
‑specific, may provide the highest level of diagnostic accuracy. These criteria 
should be considered as part of the “cumulative criterion” when screening 
patients with cardiovascular diseases for LVH.
O R I G I N A L  A R T I C L E  ECG and CMR imaging in the detection of LVH 891
test. Correlations between 2 continuous variables 
were assessed using the Pearson or Spearman 
rank correlation, as appropriate. Proportions were 
compared to test for differences in positive LVH 
diagnoses based on ECG ­LVH criteria. Receiver 
operating characteristics were analyzed to find 
the best variable to differentiate patients with 
and without LVH. Moreover, specificity, sensi­
tivity, positive predictive value, negative predic­
tive value, accuracy, and negative likelihood ra­
tio were calculated for each tested ECG ­LVH cri­
terion. The McNemar test was used to evaluate 
the agreement between ECG ­LVH criteria and 
the diagnosis of CMR ­LVH. A P value less than 
0.05 was considered significant. Statistical analy­
ses were performed using the IBM SPSS Statistics 
software, version 25 (IBM Corp., Armonk, New 
York, United States). The Statistica (version 13.3; 
TIBCO Software, Inc., Palo Alto, California, Unit­
ed States) software was used to compare areas un­
der the curves (AUCs) in the analyses of receiver 
operating characteristics (Hanley and McNeil for­
mula). Confidence intervals were calculated, and 
proportions were compared using the MedCalc 
software (available at: https://www.medcalc.org/).
results The  study group included 53 pa­
tients (17% women) at a median (IQR) age of 
40 (28–59.5) years. Within this group, hyperten­
sion was present in 23 patients (43.4%), dyslip­
idemia in 19 (35.8%), diabetes in 5 (9.4%), atri­
al fibrillation in 8 (15.1%), history of smoking in 
(90.6%). If appropriate, other techniques such as 
short tau inversion recovery, double inversion re­
covery, and triple inversion recovery were used. 
The American Heart Association model for LV 
segmentation was applied. Left ventricular mass 
was assessed using the QMass® MR analysis soft­
ware, version 7.6 (Medis Medical Imaging Sys­
tems bv, Leiden, the Netherlands). We used 6 dif­
ferent criteria to diagnose LVH by CMR imaging 
(CMR ­LVH). Here, LVH was defined as LVM >148 g 
for men or >96 g for women according to Peters­
en et al.23 Left ventricular hypertrophy was also 
assessed after LVMi to body surface area (BSA) 
(LVM / BSA), height1.7 (LVM / height1.7), height2.7 
(LVM / height2.7), or to the percentage of predict­
ed LVM (%pLVM), according to cutoff values 
determined in the Multi ­Ethnic Study of Ath­
erosclerosis (MESA) (Supplementary material, 
Table S1).22,24-26 Additionally, LVM / BSA with cut­
off values indicating LVH proposed by Petersen et 
al23 were used. Predicted LVM (pLVM) was calcu­
lated using the following MESA equations: pLVM 
= 8.17 × height (in meters)0.561 × weight (in kilo­
grams)0.608 for men and pLVM = 6.82 × height (in 
meters)0.561 × weight (in kilograms)0.608 for women.
statistical analysis Continuous variables were 
expressed as mean (SD) or median (interquartile 
range [IQR]). They were compared between the 2 
study groups using the t test or the Mann–Whit­
ney test, as appropriate. Categorical variables were 
presented as numbers and percentages and eval­
uated by the Pearson χ2 test or the Fisher exact 
Figure 1 The electrocardiogram recording at a paper speed of 25 mm/s and calibration of 10 mm/mV showing the methodology of the electrocardiographic 
assessment of left ventricular hypertrophy. The electrocardiographic criteria for the diagnosis of left ventricular hypertrophy were based on previous studies.4,6 -8,14
 Abbreviations: F, female; M, male; R, R wave amplitude; S, S wave amplitude; SD, the deepest S wave in any single lead
S V1 + R V5 or V6 >3.5 mV; (S V1 + R V5 or V6) × QRS ≥371 mV × ms
R I + S III >2.5 mV 
S V2 + R V5  
or V6 >4.5 mV 
S V4 + SD 
≥2.3 mV (F)  
or  
≥2.8 mV (M) 
R V5 or V6 >2.6 mV
R aVL >1.1 mV; R aVL + S V3 >2.8 mV (M) or >2 mV (F);  
R aVL × QRS >103 mV × ms; (R aVL + S V3) × QRS duration (M), 
(R aVL + S V3 + 0.8 mV) × QRS duration (F) ≥244 mV × ms
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Table 2 Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy parameters in the study patients with and without left 
ventricular hypertrophy, based on nonindexed left ventricular mass
ECG ‑LVH criteria parameters LVM >148 g (M) 
or >96 g (F) (n = 36)
LVM ≤148 g (M) 
or ≤96 g (F) (n = 17)
P value
R wave amplitude in V5 or V6, mV 1.2 (0.9–1.7) 1.2 (1–1.7) 0.82
S wave amplitude in V1 + R wave amplitude in V5 or V6, mV 2.28 (1.7–2.7) 1.9 (1.5–2.4) 0.23
(S wave amplitude in V1 + R wave amplitude in V5 or V6) × QRS duration, 
mV × ms
192 (132–251.8) 170.5 (128–214) 0.35
S wave amplitude in V2 + R wave amplitude in V5 or V6, mV 2.7 (1) 2.5 (1.1) 0.50
R wave amplitude in aVL, mV 0.4 (0.2–0.7) 0.2 (0.1–0.4) 0.02
R wave amplitude in aVL × QRS duration, mV × ms 36 (16–56) 22 (8–33) 0.03
R wave amplitude in aVL + S wave amplitude in V3, mV 1.5 (0.8) 1.16 (0.6) 0.08
(R wave amplitude in aVL + S wave amplitude in V3) × QRS duration (M), 
(R wave amplitude in aVL + S wave amplitude in V3 + 0.8 mV) × QRS duration 
(F), mV × ms
152 (73–215.6) 104 (58–140.3) 0.08
R wave amplitude in I + S wave amplitude in III, mV 0.8 (0.6–1.4) 0.65 (0.5–0.9) 0.07
SD + S wave amplitude in V4, mV 2.6 (1.7–3.2) 1.7 (1.5–2.4) 0.05
Data are presented as mean (SD) or median (interquartile range).
Abbreviations: ECG, electrocardiography; LVH, left ventricular hypertrophy; others, see FIgURE 1 and TAblE 1
Table 1 Baseline characteristics of the study patients with and without left ventricular hypertrophy, based on indexed and nonindexed left 
ventricular mass
Variables LVM >148 g (M) 
or >96 g (F) 
(n = 36)
LVM ≤148 g (M) 
or ≤96 g (F)  
(n = 17)
P value LVM / BSA >72 g/m2 (M) 
or >55 g/m2 (F) (n = 38)
LVM / BSA ≤72 g/m2 (M) 
or ≤55 g/m2 (F) (n = 15)
P value
Demographic characteristics
Age, y, median (IQR) 44 (32.3–59) 29 (24.5–63.5) 0.33 44.5 (29.8–60.3) 33 (25–46) 0.13
Female sex, n (%) 8 (22.2) 1 (5.9) 0.24a 8 (21.1) 1 (6.7) 0.42a
Cardiovascular diseases and risk factors, n (%)
HF 23 (63.9) 6 (35.3) 0.05 24 (63.2) 5 (33.3) <0.05
CAD 14 (38.9) 6 (35.3) 0.80 15 (39.5) 5 (33.3) 0.68
Diabetes 4 (11.1) 1 (5.9) 1a 4 (10.5) 1 (6.7) 1a
Hypertension 16 (44.4) 7 (41.2) 0.82 17 (44.7) 6 (40) 0.75
Dyslipidemia 15 (41.7) 4 (23.5) 0.20 16 (42.1) 3 (20) 0.13
History of smoking 9 (25) 5 (29.4) 0.73 11 (28.9) 3 (20) 0.51
AF 8 (22.2) 0 0.04a 7 (18.4) 1 (6.7) 0.42a
CMR parameters, mean (SD) or median (IQR)
LVEF, % 43.3 (14.9) 55 (11.6) 0.006 43.2 (14.8) 56.7 (10) 0.002
LVEDV, ml 174.6 (163–232.9) 141 (122.7–188.9) 0.01 174.6 (159.1–235.4) 146 (122.5–189.6) 0.02
LVESV, ml 110.1 (80.2–145.5) 66.6 (55.6–73.9) <0.001 98.6 (78–154.4) 65.6 (52.9–74.1) 0.001
a  Fisher exact test (exact significance, 2-tailed).
Abbreviations: AF, atrial fibrillation; BSA, body surface area; CAD, coronary artery disease; CMR, cardiac magnetic resonance; LVEDV, left ventricular end -diastolic volume; 
LVESV, left ventricular end ‑systolic volume; HF, heart failure; IQR, interquartile range; LVEF, left ventricular ejection fraction; LVM, left ventricular mass; others, see FIgURE 1
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was diagnosed in 3.8% of patients using the Cor­
nell voltage and for S wave amplitude in V2 + R 
wave amplitude in lead V5 or V6 >4.5 mV. For R 
wave amplitude in lead aVL >1.1 mV, ECG ­LVH 
was detected in 5.7% of the study patients, while 
for the Sokolow–Lyon voltage and R wave ampli­
tude in lead aVL × QRS duration >103 mV × ms, it 
was detected in 7.5% of the patients. For the Cor­
nell product, ECG ­LVH was observed in 9.4% of 
the patients, and for at least 1 positive ECG­LVH 
criterion, the prevalence of ECG ­LVH was 49.1%.
Before indexation, median (IQR) R wave am­
plitude in lead aVL and median (IQR) R wave am­
plitude in lead aVL × QRS duration were high­
er in patients with LVH as determined by CMR 
imaging, compared with patients without LVH 
(0.4 [0.2–0.7] mV vs 0.2 [0.1–0.4] mV; P = 0.02 
and 36 [16–56] mV × ms vs 22 [8–33] mV × ms; 
P = 0.03, respectively) (TAblE 2). After LVMi, values 
used to calculate the Peguero–Lo Presti, Cornell 
voltage, Cornell voltage–duration product, and 
Sokolow–Lyon product criteria performed bet­
ter than parameters calculated in other ECG­
­LVH criteria and were generally higher in pa­
tients with LVH as compared with those with­
out LVH (Supplementary material, Tables S2–S6).
14 (26.4%), coronary artery disease in 20 (37.7%), 
and heart failure in 29 (54.7%). The mean (SD) 
left ventricular ejection fraction was 47% 
(14.9%), the median (IQR) left ventricular end­
­diastolic volume was 172.5 (146.2–220.1) ml, 
and the  median (IQR) left ventricular end­
­systolic volume was 91.7 (66.1–121.5) ml. Late 
gadolinium enhancement was observed in 41 
patients (85%) in whom gadolinium contrast 
was administered. The baseline characteristics 
of patients with or without LVH based on non­
indexed LVM and LVM indexed for BSA, accord­
ing to cutoff values proposed by Petersen et al,23 
are shown in TAblE 1. For other LVMi methods, no 
significant differences in baseline characteris­
tics were found between patients with and with­
out LVH (data not shown).
The prevalence of CMR ­LVH was 67.9% for 
nonindexed LVM, 71.7% for LVM / BSA, 17% for 
LVM / height1.7, 15.1% for LVM / height2.7, 15.1% 
for LVM / BSA (MESA), and 11.3% for %pLVM. 
For a single criterion, the prevalence of ECG ­LVH 
ranged from 1.9% (for R wave amplitude in  leads 
V5 / V6 >2.6 mV, the Sokolow–Lyon product, and 
the Gubner–Ungerleider criterion) to 45.3% (for 
the Peguero–Lo Presti criterion). Also, ECG ­LVH 
Table 3 Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy in the study patients with and without left ventricular 
hypertrophy, based on nonindexed left ventricular mass
Positive ECG ‑LVH criteria LVM >148 g (M) or >96 g (F) (n = 36) LVM ≤148 g (M) or ≤96 g (F) (n = 17) McNemar 
test
P value
TP FN FP TN
R wave amplitude in V5 or V6 >2.6 mV 1 (2.8) 35 (97.2) 0 17 (100) <0.001 1a
S wave amplitude in V1 + R wave amplitude 
V5 or V6 >3.5 mV
3 (8.3) 33 (91.7) 1 (5.9) 16 (94.1) <0.001 1a
(S wave amplitude in V1 + R wave 
amplitude in V5 or V6) × QRS 
duration ≥371 mV × ms
1 (2.8) 35 (97.2) 0 17 (100) <0.001 1a
S wave amplitude in V2 + R wave amplitude 
in V5 or V6 >4.5 mV
1 (2.8) 35 (97.2) 1 (5.9); 16 (94.1) <0.001 0.54a
R wave amplitude in aVL >1.1 mV 3 (8.3) 33 (91.7) 0 17 (100) <0.001 0.54a
R wave amplitude in aVL × QRS 
duration >103 mV × ms
4 (11.1) 32 (88.9) 0 17 (100) <0.001 0.29a
R wave amplitude in aVL + S wave 
amplitude in V3 >2.8 mV (M) or >2 mV (F)
2 (5.6) 34 (94.4) 0 17 (100) <0.001 1a
(R wave amplitude in aVL + S wave 
amplitude in V3) × QRS duration (M), (R wave 
amplitude in aVL + S wave amplitude in V3 
+ 0.8 mV) × QRS duration (F) ≥244 mV × ms
5 (13.9) 31 (86.1) 0 17 (100) <0.001 0.16a
R wave amplitude in I + S wave amplitude 
in III >2.5 mV
1 (2.8) 35 (97.2) 0 17 (100) <0.001 1a
SD + S wave amplitude in V4 ≥2.3 mV (F) 
or ≥2.8 mV (M)
21 (58.3) 15 (41.7) 3 (17.6) 14 (82.4) 0.01 0.005
At least 1 positive ECG‑LVH criterion 22 (61.1) 14 (38.9) 4 (23.5) 13 (76.5) 0.03 0.01
Data are presented as number (percentage).
a  Fisher exact test (exact significance, 2-tailed)
Abbreviations: FN, false negative; FP, false positive; TN, true negative; TP, true positive; others, see FIgURE 1 and TAblEs 1 and 2
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When ECG ­LVH criteria were analyzed as cate­
gorical variables, we observed that only the Pegue­
ro–Lo Presti and at least 1 positive ECG­LVH cri­
terion were more frequently positive in patients 
with CMR ­LVH diagnosed based on nonindexed 
LVM compared with the remainder of patients 
(58.3% vs 17.6%; P = 0.005 and 61.1% vs 23.5%; P = 
0.01, respectively) (TAblE 3). Importantly, before and 
after LVMi, different criteria were more accurate 
in patients with LVH as determined by CMR im­
aging compared with patients without LVH. After 
LVMi, the Peguero–Lo Presti criterion and at least 
1 positive ECG­LVH criterion were more frequent­
ly positive in patients with CMR ­LVH diagnosed 
based on the cutoff criteria for CMR ­LVH, consid­
ering all LVMi methods (Supplementary material, 
Tables S7–S11). In addition, for %pLVM, LVM / BSA 
(MESA), LVM / height1.7, and LVM / height2.7 in­
dexing methods, the Cornell product was more 
frequently positive in patients with CMR ­LVH 
than in those without CMR ­LVH. When apply­
ing the comparison of proportion to these 3 
differentiation criteria, the Peguero–Lo Presti 
criterion and at least 1 positive ECG­LVH cri­
terion differed from the Cornell product (dif­
ference for LVM / BSA [MESA], 62.5%; 95% CI, 
17–86.3; P = 0.009; difference for LVM / height1.7, 
55.6%; 95% CI, 9–78.8; P = 0.02; difference for 
LVM / height2.7, 50%; 95% CI, 2.9–75.9; P = 0.046), 
whereas there was a trend in difference in the case 
of %pLVM (50%; 95% CI, 0.006–81.2; P = 0.06). 
At the same time, the Peguero–Lo Presti crite­
rion and at least 1 positive ECG­LVH criterion 
did not differ (data not shown). The McNemar 
test revealed that the majority of ECG ­LVH cri­
teria were in agreement with CMR ­LVH when 
%pLVM as an LVMi method was used. None of 
the ECG ­LVH criteria were in agreement with 
CMR ­LVH when defined with nonindexed LVM 
and LVM / BSA with cutoff values proposed by 
Petersen et al23 (TAblE 3 and Supplementary mate­
rial, Table S8).
The Sokolow–Lyon product, S wave amplitude 
in lead V2 + R wave amplitude in lead V5 / V6, R 
wave amplitude in lead aVL × QRS duration, 
Cornell voltage, and Peguero–Lo Presti volt­
age parameters correlated with LVM (R = 0.27, 
P <0.05; R = 0.33, P = 0.01; R = 0.27, P <0.05; 
R = 0.36, P = 0.008; and R = 0.46, P = 0.001, re­
spectively; Supplementary material, Table S12). 
The Sokolow–Lyon voltage, Sokolow–Lyon prod­
uct, S wave amplitude in lead V2 + R wave am­
plitude in lead V5 / V6, R wave amplitude in lead 
aVL, R wave amplitude in lead aVL × QRS du­
ration, Cornell voltage, Cornell voltage–dura­
tion product, Gubner ­Ungerleider criterion, and 
Peguero–Lo Presti criterion parameters corre­
lated with indexed LVM (Supplementary ma­
terial, Table S12).
Sensitivities of ECG criteria for LVH were 
highest when all criteria were applied together 
(at least 1 ECG­LVH criterion was positive) and 
Table 4 Electrocardiographic criteria in the diagnostic workup of left ventricular 
hypertrophy and their sensitivity and specificity. Data are shown for indexed and 
nonindexed left ventricular mass (continued on the next page).
ecg ‑lVh criteria Indexed and 
nonindexed LVM
Sensitivity Specificity
R wave amplitude 
in V5 or V6 >2.6 mV
LVM 2.8 (0.1–14.5) 100 (80.5–100)
LVM / BSA (MESA) 0 (0–36.9) 97.8 (88.2–99.9)
LVM / BSA 2.6 (0.1–13.8) 100 (78.2–100)
LVM / height1.7 0 (0–33.6) 97.7 (88–99.9)
LVM / height2.7 0 (0–36.9) 97.8 (88.2–99.9)
%pLVH 0 (0–45.9) 97.9 (88.7–100)
S wave amplitude 
in V1 + R wave 
amplitude in V5 or 
V6 >3.5 mV
LVM 8.3 (1.8–22.5) 94.1 (71.3–99.85)
LVM / BSA (MESA) 25 (3.2–65.1) 95.6 (84.9–99.5)
LVM / BSA 7.9 (1.7–21.4) 93.3 (68.1–99.8)
LVM / height1.7 22.2 (2.8–60) 95.5 (84.5–99.4)
LVM / height2.7 25 (3.2–65.1) 95.6 (84.9–99.5)
%pLVH 33.3 (4.3–77.7) 95.7 (85.5–99.5)
(S wave amplitude 
in V1 + R wave 
amplitude in V5 
or V6) × QRS 
duration ≥371 
mV × ms
LVM 2.8 (0.1–14.5) 100 (80.5–100)
LVM / BSA (MESA) 12.5 (0.3–52.7) 100 (92.1–100)
LVM / BSA 2.6 (0.1–13.8) 100 (78.2–100)
LVM / height1.7 11.1 (0.3–48.3) 100 (92–100)
LVM / height2.7 12.5 (0.3–52.7) 100 (92.1–100)
%pLVH 16.7 (0.4–64.1) 100 (92.5–100)
S wave amplitude 
in V2 + R wave 
amplitude in V5 
or V6 >4.5 mV
LVM 2.8 (0.1–14.5) 94.1 (71.3–99.9)
LVM / BSA (MESA) 0 (0–36.9) 95.6 (84.9–99.5)
LVM / BSA 5.3 (0.6–17.8) 100 (78.2–100)
LVM / height1.7 0 (0–33.6) 95.5 (84.5–99.4)
LVM / height2.7 0 (0–36.9) 95.6 (84.9–99.5)
%pLVH 0 (0–45.9) 95.7 (85.5–99.5)
R wave amplitude 
in aVL >1.1 mV
LVM 8.3 (1.8–22.5) 100 (80.5–100)
LVM / BSA (MESA) 12.5 (0.3–52.7) 95.6 (84.9–99.5)
LVM / BSA 7.9 (1.7–21.4) 100 (78.2–100)
LVM / height1.7 11.1 (0.3–48.3) 95.5 (84.5–99.4
LVM / height2.7 12.5 (0.3–52.7) 95.6 (84.9–99.5)
%pLVH 16.7 (0.4–64.1) 95.7 (85.5–99.5)
R wave amplitude 
in aVL × QRS duration 
>103 mV × ms
LVM 11.1 (3.1–26.1) 100 (80.5–100)
LVM / BSA (MESA) 25 (3.2–65.1) 95.6 (84.9–99.5)
LVM / BSA 10.5 (2.9–24.8) 100 (78.2–100)
LVM / height1.7 22.2 (2.8–60) 95.5 (84.5–99.4)
LVM / height2.7 25 (3.2–65.1) 95.6 (84.9–99.5)
%pLVH 33.3 (4.3–77.7) 95.7 (85.5–99.5)
R wave amplitude in 
aVL + S wave 
amplitude in V3 
>2.8 mV (M) or >2 mV 
(F)
LVM 5.6 (0.7–18.7) 100 (80.5–100)
LVM/BSA (MESA) 12.5 (0.3–52.7) 97.8 (88.2–99.9)
LVM / BSA 5.3 (0.6–17.8) 100 (78.2–100)
LVM / height1.7 11.1 (0.3–48.3) 97.7 (88–99.9)
LVM / height2.7 12.5 (0.3–52.7) 97.8 (88.2–99.9)
%pLVH 16.7 (0.4–64.1) 97.9 (88.7–100)
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The R wave amplitude in lead aVL (AUC, 0.694; 
P = 0.02) and R wave amplitude in lead aVL × QRS 
duration (AUC, 0.686; P = 0.03) were the only 
predictors of CMR ­LVH when LVM was not in­
dexed (FIgURE 2, TAblE 5). There was no difference in 
AUC between these 2 criteria (P = 0.55). After 
LVMi, the Cornell voltage–duration product, 
Peguero–Lo Presti criterion, and Cornell voltage 
were the best predictors of CMR ­LVH (TAblE 5 and 
Supplementary material, Figures S1–S5). There 
was no difference in AUC between these 3 ECG­
­LVH criteria (data not shown).
dIscussIon In this study, we showed that 
LVH strongly depends on ECG­ and CMR im­
aging–based definitions. Methods of LVMi and 
specific ECG ­LVH criteria significantly contrib­
ute to LVH diagnosis. Left ventricular mass in­
dexing (except for LVM / BSA indexing accord­
ing to cutoff values proposed by Petersen et al23) 
was associated with a lower rate of CMR ­LVH. 
These data confirm the need to use appropriate 
indexation methods during LVM assessment.
Our observations are in line with those of pre­
vious studies, which have shown that ECG ­LVH 
criteria generally have low sensitivity yet high 
specificity for LVH diagnosis.3,27,28 The diagnostic 
efficiency of ECG ­LVH criteria differs depending 
on the study, with a sensitivity of approximately 
50% and a specificity of nearly 90%.29 The sensitiv­
ity of ECG ­LVH criteria is related to the character­
istics of the study group, including the frequency 
of LVH.9,30 In a hypertensive population, the sen­
sitivity of ECG ­LVH criteria (Gubner–Ungerleider, 
Sokolov–Lyon voltage, Cornell criteria, and Rom­
hilt–Estes score) ranged from 0% to 68%, where­
as specificity ranged from 53% to 100%.9 Our 
observations support previous findings regard­
ing the assessment of individual ECG ­LVH cri­
teria, indicating the relatively high sensitivity of 
the Cornell product and Peguero–Lo Presti crite­
rion in the diagnosis of ECG ­LVH.6,31,32 The low 
sensitivity of ECG ­LVH criteria may also result 
from the strict threshold values of ECG ­LVH cri­
teria, while the electrical activity of the heart ob­
served on ECG, which reflects LVH, depends on 
multiple factors, including body weight, sex, race, 
and age.12,27,33 Of note, the Cornell and the Pegue­
ro–Lo Presti criteria are sex ­specific, which may 
be an important factor contributing to their bet­
ter clinical performance.
Importantly, we have shown that the sensitivity 
of ECG ­LVH detection using the Peguero–Lo Presti 
criterion was also similar to using all ECG ­LVH 
criteria together (“cumulative criterion”), which 
ranged from 57.9% to 100% (according to var­
ious LVMi methods). Moreover, the specifici­
ty of the Peguero–Lo Presti criterion was sim­
ilar to that of the “cumulative criterion” ap­
proach. Taken together, it appears that the in­
clusion of the Peguero–Lo Presti criterion in 
Table 4 Electrocardiographic criteria in the diagnostic workup of left ventricular 
hypertrophy and their sensitivity and specificity. Data are shown for indexed and 
nonindexed left ventricular mass (continued from the previous page).
ecg ‑lVh criteria Indexed and 
nonindexed LVM
Sensitivity Specificity
(R wave amplitude 
in aVL + S wave 
amplitude in 
V3) × QRS duration (M), 
(R wave amplitude 
in aVL + S wave 
amplitude 
in V3 + 0.8 mV) × QRS 
duration (F) 
≥244 mV × ms
LVM 13.9 (4.7–29.5) 100 (80.5–100)
LVM / BSA (MESA) 37.5 (8.5–75.5) 95.6 (84.9–99.5)
LVM / BSA 13.2 (4.4–28.1) 100 (78.2–100)
LVM / height1.7 33.3 (7.5–70.1) 95.5 (84.5–99.4)
LVM / height2.7 37.5 (8.5–75.5) 95.6 (84.9–99.5)
%pLVH 50 (11.8–88.2) 95.7 (85.5–99.5)
R wave amplitude in 
I + S wave amplitude 
in III >2.5 mV
LVM 2.8 (0.1–14.5) 100 (80.5–100)
LVM / BSA (MESA) 0 (0–36.9) 97.8 (88.2–99.9)
LVM / BSA 2.6 (0.1–13.8) 100 (78.2–100)
LVM / height1.7 0 (0–33.6) 97.7 (88–99.9)
LVM / height2.7 0 (0–36.9) 97.8 (88.2–99.9)
%pLVH 0 (0–45.9) 97.9 (88.7–100)
SD + S wave amplitude 
in V4 ≥2.3 mV (F) 
or ≥2.8 mV (M)
LVM 58.3 (40.8–74.5) 82.4 (56.6–96.2)
LVM / BSA (MESA) 100 (63.1–100) 64.4 (48.8–78.1)
LVM / BSA 55.3 (38.3–71.4) 80 (51.9–95.7)
LVM / height1.7 88.9 (51.8–99.7) 63.6 (47.8–77.6)
LVM / height2.7 87.5 (47.4–99.7) 62.2 (46.5–76.2)
%pLVH 100 (54.1–100) 61.7 (46.4–75.5)
At least 1 positive 
ECG‑LVH criterion
LVM 61.1 (43.5–76.9) 76.5 (50.1–93.2)
LVM / BSA (MESA) 100 (63.1–100) 60 (44.3–74.3)
LVM / BSA 57.9 (40.8–73.7) 73.3 (44.9–92.2)
LVM / height1.7 88.9 (51.8–99.7) 59.1 (43.3–73.7)
LVM / height2.7 87.5 (47.4–99.7) 57.8 (42.2–72.3)
%pLVH 100 (54.1–100) 57.5 (42.2–71.7)
Data are presented as percentage (95% CI).
Abbreviations: MESA, Multi ‑Ethnic Study of Atherosclerosis; others, see FIgURE 1 and TAblEs 1 and 2
ranged from 57.9 (95% CI, 40.8–73.7) to 100 (95% 
CI, 63.1–100), depending on LVMi methods used. 
For a single criterion, the Peguero–Lo Presti  cri­
terion showed the highest sensitivity as com­
pared with other ECG ­LVH criteria and ranged 
from 55.3% (95% CI, 38.3–71.4) to 100% (95% CI, 
54.1–100), according to various LVM indexing 
methods. However, specificity of these criteria 
was generally lower compared with other crite­
ria and ranged from 57.5% (95% CI, 42.2–71.7) 
to 76.5% (95% CI, 50.1–93.2) for at least 1 posi­
tive ECG ­LVH criterion and from 61.7 (95% CI, 
46.4–75.5) to 82.4 (95% CI, 56.6–96.2) for 
the Peguero–Lo Presti criterion (TAblE 4). Posi­
tive predictive value, negative predictive val­
ue, accuracy, and the negative likelihood ratio 
of all the analyzed ECG ­LVH criteria are shown 
in Supplementary material, Table S13.
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Table 5 Area under the curve analyses according to various left ventricular hypertrophy definitions based on indexed and nonindexed left 
ventricular mass
ecg ‑lVh criteria parameters LVM >148 g (M) 
or >96 g (F) 
%pLVM >1.31 LVM / BSA 
(MESA) >106.2 g/m2 
(M) or >84.6 g/m2 (F)
LVM / BSA 
>72 g/m2 (M) 
or >55 g/m2 (F)
lVm / height1.7 
≥80 g/m1.7 (m) 
or ≥60 g/m1.7 (F)
lVm / height2.7 
>45.1 g/m2.7 (m) 
or >38 g/m2.7 (F)
R wave amplitude in V5 or V6, mV 0.480 (0.82) 0.388 (0.38) 0.451 (0.66) 0.562 (0.48) 0.455 (0.67) 0.394 (0.35)
S wave amplitude in V1 + R wave 
amplitude in V5 / V6, mV
0.602 (0.23) 0.651 (0.23) 0.628 (0.25) 0.666 (0.06) 0.631 (0.22) 0.596 (0.39)
(S wave amplitude in V1 + R wave 
amplitude in V5 / V6) × QRS 
duration, mV × ms
0.580 (0.35) 0.690 (0.13) 0.668 (0.13) 0.630 (0.14) 0.693 (0.07) 0.650 (0.18)
S wave amplitude in V2 + R wave 
amplitude in V5/V6, mV
0.565 (0.45) 0.644 (0.26) 0.696 (0.08) 0.603 (0.25) 0.643 (0.18) 0.599 (0.38)
R wave amplitude in aVL, mV 0.694 (0.02) 0.729 (0.07) 0.599 (0.38) 0.646 (0.10) 0.636 (0.20) 0.663 (0.15)
R wave amplitude in aVL × QRS 
duration, mV × ms
0.686 (0.03) 0.727 (0.07) 0.607 (0.34) 0.644 (0.11) 0.648 (0.17) 0.665 (0.14)
R wave amplitude in aVL + S 
wave amplitude in V3, mV
0.621 (0.16) 0.816 (0.01) 0.819 (0.004) 0.621 (0.17) 0.756 (0.02) 0.738 (0.03)
(R wave amplitude in aVL + S wave 
amplitude in V3) × QRS duration 
(M), (R wave amplitude in aVL 
+ S wave amplitude in V3 + 0.8 
mV) × QRS duration (F), mV × ms
0.648 (0.09) 0.853 (0.005) 0.835 (0.003) 0.639 (0.12) 0.831 (0.002) 0.811 (0.005)
R wave amplitude in I + S wave 
amplitude in III, mV
0.657 (0.07) 0.699 (0.12) 0.576 (0.49) 0.566 (0.46) 0.620 (0.26) 0.642 (0.21)
SD + S wave amplitude in V4, mV 0.667 (0.05) 0.846 (0.006) 0.876 (0.001) 0.682 (0.04) 0.799 (0.005) 0.779 (0.01)
Data are presented as the area under the curve (P value).
Abbreviations: see FIgURE 1 and TAblEs 1 and 2
Figure 2 The area under the curve of electrocardiographic criteria for the diagnosis of left ventricular hypertrophy parameters representing the predictive 
performance for left ventricular hypertrophy, based on nonindexed left ventricular mass 
 Abbreviations: see FIgURE 1 and TAblE 1
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identification of true positive and true nega­
tive cases of LVH based solely on ECG ­LVH cri­
teria may be misleading. The Peguero–Lo Presti 
criterion and the Cornell criteria, which are 
sex ­specific, may provide the highest level of 
diagnostic accuracy and should be considered 
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the “cumulative criterion” is advantageous when 
comparing proportions and AUC results for sin­
gle parameters. Furthermore, owing to its high 
sensitivity, using the Peguero–Lo Presti criteri­
on as an individual criterion appears to be a good 
screening test for LVH in real ­world patients with 
cardiovascular diseases. However, it should be 
noted that the Peguero–Lo Presti criterion was 
related to a significant number of false ­positive 
results in our study cohort. Moreover, Sun et al12 
have shown that the novel Peguero–Lo Presti cri­
terion may not be a better ECG ­LVH criterion in 
Asian populations as compared with the previ­
ously used criteria. Thus, more studies compar­
ing this criterion to the previously used ECG ­LVH 
criteria in various groups of patients are needed.
Left ventricular hypertrophy is generally de­
fined as an increased LVM; however, LVM is not 
the only factor influencing QRS changes, such 
as QRS voltage and duration.34 Myocardial isch­
emia, remodeling, including cardiomyocyte hy­
pertrophy or fibrosis, and changes in the elec­
trical properties of the myocardium, such as 
the presence of conduction blocks, are factors 
determining QRS characteristics.29,35 These fac­
tors, at least in part, contribute to the observed 
discrepancies between ECG ­LVH and CMR ­LVH. 
Cardiac magnetic resonance imaging, reflecting 
myocardial structural alterations, and ECG, in­
dicating the electrical properties of the myocar­
dium, could be used together in a comprehen­
sive myocardial assessment and, combined, may 
better predict cardiovascular outcomes.
limitations Our study had several limita­
tions, which should be acknowledged. Elec­
trocardiography and CMR imaging were not 
always performed on the same day. However, 
the median (IQR) interval between ECG record­
ing and CMR imaging was 1 (0–4) day. We ex­
cluded patients having an ECG of inappropri­
ate quality for analysis, which could have influ­
enced selection of the study participants. Our 
study cohort was small in size; however, even 
in this group, we could determine differences 
in the tested ECG ­LVH criteria and suggest po­
tentially the most significant ECG ­LVH criteria. 
The majority of the study patients had previous­
ly diagnosed cardiovascular diseases and / or 
late gadolinium enhancement, which could af­
fect QRS characteristics as well as sensitivity 
and specificity of the analyzed ECG ­LVH cri­
teria. However, we did not aim to propose new 
cutoff values of established ECG ­LVH criteria 
in our study. Our observations should be con­
firmed in a larger group of patients. Finally, our 
results may not be fully applicable in a general 
population without comorbidities.
conclusions The diagnosis of LVH strong­
ly depends on ECG­ and CMR imaging–based 
definitions. In clinical practice, the proper 
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